DIABETIC MACULAR EDEMA

This study examines how well a biosimilar (a lower-cost copy) of the drug ranibizumab works for diabetic macular edema, a condition that causes vision loss in people with diabetes. Researchers will review medical records of 60 adults who received at least one injection of the bio…

This study tests an experimental drug called RO7446603, given alone or with existing medications (aflibercept or faricimab), for people with diabetic macular edema—a condition that causes vision loss due to diabetes. The trial has two parts: an early safety phase (Phase I) and a …

This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is t…

This early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check saf…

This study tested an oral medication called APX3330 in 103 adults with moderate to severe diabetic retinopathy, a leading cause of vision loss. The pill aims to reduce inflammation and low-oxygen stress in the eye. Researchers measured whether the drug could improve the severity …

This study tested a new eye medication called PRO-169 against a standard drug (ranibizumab) for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. About 509 adults with diabetes took part, receiving injections into the eye over one ye…

This phase 2 trial tested a new drug called vamikibart, given as an eye injection, for people with diabetic macular edema—a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. The study involved 394 participants and compared vamikiba…

This study tested OCS-01, a steroid eye drop, in 552 people with diabetic macular edema (DME), a condition where fluid builds up in the eye and blurs vision. Participants used the drops several times daily for up to a year. The goal was to see if the drops improve vision and redu…

This study tested whether a steroid eye drop called OCS 01 can improve vision in people with diabetic macular edema, a common cause of vision loss in diabetes. Over 400 participants used the drops several times daily for a year. The goal was to see if this non-invasive treatment …

This study tested the safety and effectiveness of brolucizumab, a drug injected into the eye, for treating diabetic macular edema (DME) in 66 Indian patients. DME is a complication of diabetes that can cause vision loss. The study aimed to see how well the drug works in real-worl…

This study looked at whether faricimab injections can help people with diabetic retinopathy, a diabetes-related eye disease. Over 12 months, 60 patients received the treatment and doctors measured changes in the back of the eye. The goal was to see if the drug could reduce abnorm…

This study tested whether a higher dose (8 mg) of the drug aflibercept, given every 16 weeks, works as well as the standard dose (2 mg) given every 8 weeks for Chinese people with diabetic macular edema (DME), a diabetes-related eye condition that causes vision problems. 333 part…

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with diabetic macular edema (DME). About 1,500 patients who had completed earlier studies received faricimab at personalized intervals. The main goal was to track side effects, no…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This phase 2a trial tested a new biologic drug called AG-73305, given as an injection into the eye, in 25 adults with diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The study aimed to check the drug's safety and how well it works over 6 month…

This Phase II trial tested whether adding vamikibart to the standard treatment ranibizumab improves vision more than ranibizumab alone in people with diabetic macular edema. 187 participants received injections into the eye over 76 weeks. The study is complete, and results will s…

This study tested an experimental drug called RZ402 in 94 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. The goal was to see if the drug is safe and can reduce swelling in the retina and improve eyesight compared to a placebo. Par…

This study tested whether a steroid implant (Ozurdex) or anti-VEGF injections (Avastin, Lucentis, or Eylea) work better to prevent worsening of diabetic macular edema after cataract surgery. Sixteen adults with diabetes and pre-existing eye swelling received one treatment before …

This study tested the safety of aflibercept, an already-approved eye injection, in 100 Indian adults with diabetic macular edema (DME). Participants received injections every 4 weeks for 5 months, then every 8 weeks for a total of 48 weeks. The main goal was to track any side eff…

This phase 2 trial tested a new way to deliver dexamethasone directly to the back of the eye using tiny microspheres (OXU-001) compared to the standard Ozurdex implant. The study enrolled only 3 adults with diabetic macular edema to check safety and how well the treatment is tole…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study looked at 360,000 French patients who received eye injections for conditions like age-related macular degeneration. The goal was to find out how often a serious eye infection called endophthalmitis happens within 28 days after the injection. Researchers analyzed data f…

This study looked at whether specific features on eye imaging scans can predict how well a person with diabetic macular edema will respond to treatment. Researchers analyzed images from 32 participants to find patterns linked to better or worse outcomes. The goal is to help docto…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…